Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-05-23
2006-05-23
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C424S130100, C424S141100, C424S145100, C424S158100
Reexamination Certificate
active
07049411
ABSTRACT:
The invention provides for the isolation, identification, synthesis, expression and purification of antibodies reactive with factor IX (FIX)/factor IXa (IXa). In particular aspects, the invention provides human antibodies reactive with the human FIX Gla domain. The invention further provides compositions especially pharmaceutical compositions, articles of manufacture, and methods of inhibiting the activation of FIX and inhibiting FIX/IXa dependent coagulation.
REFERENCES:
patent: 5654407 (1997-08-01), Boyle et al.
patent: WO 91/16353 (1991-10-01), None
patent: WO 95/25167 (1995-09-01), None
patent: WO 97/26010 (1997-07-01), None
Wojcik et al. Biochim Biophys Acta, 1382(1):91-101, Jan. 15, 1998.
Ahmad and Walsh, “Platelet membrane-mediated coagulation protease complex assembly”Trends in Cardiovascular Medicine4(6):271-277 (1994).
Ahmad et al., “Coagulation factor IX residues G4-Q11mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex”Biochemistry37(6):1671-1679 (Feb. 10, 1998).
Ahmad et al., “High-affinity, specific factor IXa binding to platelets is mediated in part by residues 3-11”Biochemistry33(40):12048-12055 (Oct. 11, 1994).
Bach, R. R., “Initiation of Coagulation by Tissue Factor”CRC Critical Reviews in Biochemistry23(4):339-368 (1988).
Benedict et al., “Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model”Journal of Clinical Investigation88(5):1760-1765 (Nov. 1991).
Blackburn et al., “Anti-factor IX monoclonal antibody, BC2, is a potent antithrombotic agent”Blood(Abstract #1885) 90 (Suppl. 1):424a-425a (1997).
Cheung et al., “Identification of the endothelial cell binding site for factor IX”Proc. Natl. Acad. Sci. USA93(20):11068-11073 (Oct. 1, 1996).
Cheung et al., “The binding of human factor IX to endothelial cells is mediated by residues 3-11”Journal of Biological Chemistry267(29):20529-20531 (Oct. 15, 1992).
Davie et al., “The Coagulation Cascade: Initiation, Maintenance, and Regulation”Biochemistry30 (43):10363-10370 (1991).
Di Scipio et al., “Activation of human factor IX (Christmas factor)”Journal of Clinical Investigation61(6):1528-1538 (Jun. 1978).
Figini et al., “In Vitro Assembly of Repertoires of Antibody Chains on the Surface of Phage by Renaturation”J. Mol. Biol.239:68-78 (1994).
Fujikawa et al., “The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa(activated plasma thromboplastin antecedent)”Biochemistry13(22):4508-4516 (Oct. 22, 1974).
Heimark and Schwartz, “Binding of coagulation factors IX and X to the endothelial cell surface”Biochemical&Biophysical Research Communications111(2):723-731 (Mar. 16, 1983).
Janeway et al.Immunobiology, Garland Press, 4th edition, London NY pps. 87 (1999).
Lewis et alBlood56(4):608-614 (1980).
Lewis et al., “Isolation of CA++-dependent human antibodies to human factor IX”Circulation(abstract #1070) 62(4):III-279 (Oct. 1980).
Liebman et al., “The factor IX phospholipid-binding site is required for calcium-dependent activation of factor IX by factor XIa”Journal of Biological Chemistry262(16):7605-7612 (Jun. 5, 1987).
Liebman, H., “The metal-dependent conformational changes in factor IX associated with phospholipid binding. Studies using antibodies against a synthetic peptide and chemical modification of factor IX”European Journal of Biochemistry212(2):339-345 (Mar. 1, 1993).
Limentani et al.Hemostasis and Thrombosis Basic Principles and Clinical Practice, Chapter 5, Coleman et al. Eds., Third edition, Philadelphia:Lippincott Company (1994).
Mann et al., “Surface-dependent hemostasis”Seminars in Hematology29(3):213-226 (Jul. 1992).
Osterud and Rapaport, “Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation”Proc. Natl. Acad. Sci. USA74(12):5260-5264 (Dec. 1977).
Osterud et al., “Human blood coagulation factor IX. Purification, properties, and mechanism of activation by activated factor XI”Journal of Biological Chemistry253(17):5946-5951 (Sep. 10, 1978).
Pike et al., “Immunochemical characterization of a monoclonal γG4, λ human antibody to factor IX”Blood40(1):1-10 (Jul. 1972).
Prorok et al., “The entire γ-carboxyglutamic acid- and helical stack-domains of human coagulation factor IX are required for optimal binding to its endothelial cell receptor”International Journal of Peptide&Protein Research48:281-285 (1996).
Rawala-Sheikh et al., “Role of γ-carboxyglutamic acid residues in the binding of factor IXa to platelets and in factor-X activation”Blood79(2):398-405 (Jan. 15, 1992).
Refino et al., “A Human Antibody That Binds to the γ-Carboxyglutamic Acid Domain of Factor IX is a Potent Antithrombotic In Vivo.”Thrombosis and Haemostasis82(3):1188-1195 (Sep. 1999).
Reisner et al., “Immunochemical characterization of a polyclonal human antibody to factor IX”Blood50(1):11-19 (Jul. 1977).
Ryan et al., “Structural determinants of the factor IX molecule mediating interaction with the endothelial cell binding site are distinct from those involved in phospholipid binding”Journal of Biological Chemistry264(34):20283-20287 (Dec. 5, 1989).
Sekiya et al., “Regulation of the tertiary structure and function of coagulation factor IX by magnesium (II) ions”Journal of Biological Chemistry270(24):14325-14331 (Jun. 16, 1995).
Spanier et al., “Heparinless cardiopulmonary bypass with active-site blocked factor IXa: a preliminary study on the dog”Journal of Thoracic&Cardiovascular Surgery115(5):1179-1188 (May 1998).
Stenflo and Dahlback, “Vitamin K-Dependent Proteins”The Molecular Basis of Blood Diseases, Stamatoyannopoulos et al. eds., 2nd edition, Philadelphia, PA:Saunders pps. 565-598 (1994).
Suggett et al., “Use of phage display for the generation of human antibodies that neutralize factor IX function”Blood(abstract #2266) 92(10 suppl. 1):551a (Nov. 15, 1998).
Sugo et al., “Anti-human factor IX monoclonal antibodies specific for calcium ion-induced conformations”Thrombosis Research58(6):603-614 (Jun. 15, 1990).
Toomey et al., “The endothelial cell binding determinant of human factor IX resides in the γ-carboxyglutamic acid domain”Biochemistry31(6):1806-1808 (Feb. 18, 1992).
Wong et al., “Relative efficacy of active site-blocked factors IXa, Xa in models of rabbit venous and arterio-venous thrombosis”Thrombosis and Haemostasis77(6):1143-1147 (Jun. 1997).
Yoshitake et al., “Nucleotide sequence of the gene for human factor IX (antihemophilic factor B)”Biochemistry24(14):3736-3750 (Jul. 2, 1985).
Zhong et al., “Some human inhibitor antibodies interfere with factor VIII binding to factor IX”Blood92(1):136-142 (Jul. 1, 1998).
Braunwald, “Thrombolytic (Fibrinolytic) Drugs”Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th edition, Chapter 80, 2:2085-2086.
Fowles, Robert E., “Third-Generation Fibrinolytics”Harrison's Advances in Cardiology, Boston:McGraw-Hill Medical Publishing Division, Chapter 26, pps. 168-169.
Adams Camellia W.
Devaux Brigitte
Eaton Dan L.
Hass Philip E.
Judice J. Kevin
Blanchard David J.
Genentech Inc.
Helms Larry R.
Svoboda Craig G.
LandOfFree
Human anti-factor IX/IXa antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human anti-factor IX/IXa antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human anti-factor IX/IXa antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3575258